News
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
– Initiation of Phase 1/2 Clinical Trial Expected in Q1, 2023
1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate FB849, a small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with advanced solid tumors. Harnessing multiple components in the immune system while avoiding interfering with essential immune function is a significant challenge in immuno-oncology. FB849 as a highly selective HPK1 inhibitor has the potential to overcome these challenges.
MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients
— Orally administered MP1032 with very favorable safety and tolerability profile
— Compound equally effective as Remdesivir or Nirmatrelvir/Ritonavir as monotherapy
— Oral administration and suitability for early intervention address high unmet medical need
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, today announced topline data of its CT05 Phase IIa double-blind placebo-controlled study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients.
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
– Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Company´s management team as Head of Research and Discovery.
Dr. Burbidge is an experienced drug hunter with an in-depth expertise in both small molecule and biological drug discovery and development. He is currently Director of Discovery and Preclinical Projects at 3D Consultants, Cambridge (UK), an advisory company focusing on drug discovery and development. From 2009 to 2018, he held positions of increasing responsibility at Proximagen Ltd, Cambridge (UK), most recently as Head of Discovery and Preclinical Projects. Read more…
Allero Therapeutics Receives EIC Horizon Grant to Advance Treatment of Celiac Disease
– Specific OroMucosal ImmunoTherapy (SOMIT) for celiac disease patients supported with EUR 2.5mn funding
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced that the Company has received a EUR 2.5 million EIC Horizon Grant provided by the European Commission to advance novel treatments for celiac disease patients. The program is based on Allero´s proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform technology for the treatment of antigen-driven immune disorders.